Novo Nordisk: Commercialising stem cells
January 2010. Stem cell applications require other business models than those based on pharmacological treatments. What is the approach of Novo Nordisk compared with competitors like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis? Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk in the interview with B2Bioworld.Reading time: 10 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Novartis and Stem Cells
Mark Fishman, President Novartis Institutescomments on the company’s strategy and technology acquisitions in the field
Stem Cell Research Now and in the Future - Viewed from GSK
Sir Patrick Vallance, at the time President Pharmaceuticals, R&D of GlaxoSmithKline
Stem Cells – Failings and Deliveries
Patenting Stem Cells – Behind the Front Stages
A legal approach solving problems with patentability
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)